Andrea Giustina, Luigi di Filippo, Maria Fleseriu, Rosario Pivonello, Stephan Petersenn, John Wass, Susan L. Samson, Alberto M. Pereira, Raúl M. Luque, Betina Biagetti, Maria Chiara Zatelli, Ken K Y Ho, César Luiz Boguszewski, Aart Jan van der Lely, Mark Gurnell, Nienke Biermasz, Katharina Schilbach, Diego Ferone, Monica R Gadelha, Adriana G. Ioachimescu, E Ghigo, Christian J Strasburger, Pinar Kadioglu, Pietro Maffei, Niki Karavitaki, Mónica Marazuela, M Buchfelder, Sabrina Chiloiro, A Luger, Yona Greenman, Elena Valassi, Ignacio Bernabéu, Stefano Frara, Philippe Chanson, Thierry Brue, John Ayuk, Felipe F. Casanueva, Annamaria Colao, Pietro Mortini, Sebastian Neggers, Manel Puig-Domingo, Meliha Melin Uygur, Shlomo Melmed
The 16th Acromegaly Consensus Conference in September 2024 updated recommendations on diagnosis and treatment of acromegaly comorbidities. Since the 2020 acromegaly comorbidity management guideline was published, new evidence has emerged on novel and known comorbidities and new treatment approaches. Forty-three experts in the management of acromegaly reviewed the current literature and assessed changes in clinical practice standards and management. Current outcome goals were considered and updated, with a focus on the impact of current and emerging treatments of these comorbidities. Participants assessed factors that determine pharmacological choices, as well as use of specific agents in the management of the most relevant acromegaly comorbidities. We present consensus recommendations highlighting optimization of evidence-based acromegaly comorbidities management.